ASH 2021 | First-line ibrutinib and venetoclax in CLL
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses long-term follow-up data from a study assessing ibrutinib and venetoclax as first-line therapy in patients with chronic lymphocytic leukemia (CLL). 120 patients received the combination and after a 24 month follow-up, a majority of patients achieved a minimal residual disease (MRD) negative status. In patients who remained MRD positive, additional ibrutinib and venetoclax resulted successfully resulted in MRD negativity after another 12 month follow-up. The results are consistent with the findings from the Phase II CAPTIVATE trial (NCT02910583), highlighting ibrutinib and venetoclax as a promising therapy for CLL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
